Does trulicity cause gastroparesis or stomach paralysis?

See the DrugPatentWatch profile for trulicity

Does Trulicity increase the risk of gastroparesis?

Trulicity (dulaglutide) belongs to the GLP-1 receptor agonist class. These drugs slow gastric emptying as part of their mechanism, which can mimic or worsen symptoms that resemble gastroparesis. The FDA prescribing information lists nausea, vomiting, and abdominal pain as common side effects, and post-marketing reports have linked GLP-1 drugs to delayed gastric emptying severe enough to require medical attention.

How common is this side effect in real-world use?

Clinical trials reported gastroparesis in less than 1 % of participants, but larger observational studies and adverse-event databases show higher rates once the drug is used broadly. A 2023 analysis of the FDA Adverse Event Reporting System found a statistically significant signal for gastroparesis with dulaglutide compared with other diabetes medications.

Can symptoms resolve after stopping the drug?

Most patients see improvement within weeks to months after discontinuation, but a minority experience persistent symptoms. Recovery time varies with dose, duration of use, and individual factors such as co-existing diabetes-related nerve damage.

How does Trulicity compare with other GLP-1 drugs on this risk?

All GLP-1 agonists carry the same class warning for delayed gastric emptying. Head-to-head data are limited, yet some analyses suggest semaglutide and liraglutide have slightly higher reporting rates for gastroparesis than dulaglutide, though the absolute risk remains low for any single agent.

What should patients watch for and discuss with their doctor?

Persistent nausea, early satiety, bloating, or vomiting that does not improve after the first few weeks of treatment warrants evaluation. Doctors may order gastric emptying studies or temporarily pause therapy to distinguish drug effect from other causes.

Are there alternatives if gastroparesis develops?

Switching to a non-GLP-1 diabetes medication such as metformin, SGLT2 inhibitors, or DPP-4 inhibitors usually eliminates the gastric slowing effect. For weight-management goals, lifestyle measures or older agents like orlistat remain options without this mechanism.

When does the patent for Trulicity expire?

The composition-of-matter patent in the United States is scheduled to expire in 2027, with possible pediatric exclusivity extending protection into 2028. After expiry, multiple manufacturers have already filed for biosimilar versions.

DrugPatentWatch.com provides updated patent and exclusivity timelines for dulaglutide.